Session 1195: Novel Therapies, Part 1

Cochair(s): J Shay,
Date: Mon 11 February 2002, Time: 14:00 - 16:00
Location: Amphithéâtre Duclaux

Oral Presentations

Time Number Title / Authors / Affiliations
14:00 456 Lymphoma growth-inhibitory activity of sulfasalazine (SASP) involves inhibition of cysteine supply by somatic cells.
PW Gout, MC Robertson
BC Cancer Agency, Vancouver, Canada
14:15 457 Natural human antibody and intravenous immunoglobulin regulation of T cell activation
DA Chow, Y Li, S Hebert
University of Manitoba, Winnipeg, Canada
14:30 458 Modulation of Calcium-activated K-channels in T cells: A novel therapeutic approach?
LS Madsen, M Hertz, D Strøbæk, P Christophersen, FA Sløk, A Gautam, PhD Jensen
1Section of Ion channel Pharmacology, NeuroSearch A/S, Ballerup, Denmark, 2Poseidon Pharmaceuticals, Ballerup, Denmark, 3Pharmexa A/S, Hørsholm, Denmark
14:45 459 Control of cell proliferation via redox-regulated expression of glycolytic genes
KA Brand, U Aulwurm, D Fabian, B Hamm-Kuenzelmann, R Netzker, D Schaefer, C Weigert
University Erlangen-Nuremberg Medical Faculty, Erlangen, Bavaria Germany
15:00 460 Pharmacological perspectives of mistletoe therapy
T Hajto
Hungarian Immune Therapy Health and Service Deposit Partnership, Budapest, Hungary
15:15 461 Chemoprevention of chemically-induced intestinal carcinoma in rats by combined octreotide, galanin and serotonin treatment and by cyclooxygenese-2 inhibitor
ME El-Salhy
Public Health and clinical Medicine, Umeå, Sweden
15:30 462 Which dosing scheme is suitable for the taxanes? An in vitro model
UA Sanli, R Uslu, B Karabulut, VC Sezgin, G Saydam, SB Omay, F Buyukkececi, E Goker
Department of Hematology-Oncology Ege University Medical School, Bornova-Izmir, Izmir Turkey
15:45 463 Radiation induced shedding of TGF alpha results in a prolonged period of refractoriness to further release of TGF alpha
MP Hagan, A Yacoub
Medical College of Virginia, Richmond, Virgina United States

Poster Presentations

Number Title / Authors / Affiliations
464 The effect of retinoic acid on sodium-iodide symporter gene (NIS) expression in breast cancer and normal breast cells
M Jarzab, V Piddubnyak, J Szary, B Maka, M Wiench, B Nikiel, A Goraj-Zajac, K Lisowska, Z Krawczyk
1Dept. of Tumor Biology, Molecular Biology, , 2Dept. of Tumor Biology, Surgery, , 3Dept. of Tumor Biology, Nuclear Medicine and Endocrine Oncology, , 4Dept. of Tumor Biology, Pathology, , 5Dept. of Tumor Biology, Centre of Oncology -- Maria Sklodowska-Curie Memorial Institute, Gliwice Branch, Poland
465 *The tyrosine kinase inhibitor sti571 downregulates gene expression by reducing histone h4 acetylation and histone deacetylase (hdac) expression.
G Brusa, C Santucci, L Pattacini, M Mancini, L Mazzacurati, M Baccarani
University of Bologna Medical School, Bologna, Bologna Italy
466 Rapamycin prevents calcineurin inhibitor-associated tumor progression
M Hojo, F Luan, M Maluccio, K Yamaji, M Suthanthiran
Division of Nephrology/Transplantation Medicine New York Presbyterian Hospital/Weill Medical College of Cornell University, New York, NY USA
467 The effect of cisplatin and docetaxel on p53 and mdm2 in cancer cell lines
L Laatio, R Serpi, U Puistola, K Vahakangas
1Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland, 2Department of Obstetrics and Gynecology, University Hospital of Oulu, Oulu, Finland, 3Department of Pharmacology and Toxicology, University of Kuopio, Kuopio, Finland
468 Possible cytotoxic effects of lipophilic o-naphthoquinones in isolated rat hepatocytes; protective mechanisms.
M Dubin, F Villamil, NV De Witte, PH Carrizo, M Portela, AOM Stoppani
School of Medicine, Bioenergetics Research Centre, University of Buenos Aires, Argentina
469 *Prevention of radiation-induced pulmonary fibrosis by blockade of transforming growth factor-beta (TGF-β) signaling
A Nishioka, Y Ogawa, S Kariya, S Yoshida, H Ueno
1Department of Radiology, Kochi Medical School, Nankoku, kochi Japan, 2Department of Biochemistry and Molecular Pathophysiology, School of Medicine, University of Occupational and Environmental Health, Kitakyusyu, Fukuoka Japan
470 Peroxisome proliferators as differentiating agents: an intriguing mechanism of action.
R Scatena, G Nocca, P Bottoni, I Messana, F Vincenzoni, L Ceccarelli, B Giardina
Institute of Biochemistry and Clinical Biochemistry. Catholic University, Largo A. Gemelli, 00168- Rome, Italy
471 The radiosensitizing effect of Pentoxifylline at high dose rate compared to low dose rate irradiation.
A Danielsson, E Karlsson, C Mercke
Department of Oncology, Goteborg University, Sweden
472 In vivo genotoxkinetics: an alternative to study pharmacokinetics and pharmacodynamics of antineoplastic agent busulfan
P Morales-Ramirez
Instituto Nacional de Investigaciones Nucleares, Mexico D.F, Mexico
473 Effects of ganglioside biosynthesis inhibition on the expression and phosphorylation of the membrane tyrosine-kinase receptors p185neu/ErbB2 in tumor and normal mammary cell lines.
E Sottocornola, I Colombo, B Berra
Institute of General Physiology and Biological Chemistry, School of Pharmacy - University of Milan, Milan, Italy
474 Parathyroid carcinoma: twenty cases. Up to date in a high rate incidence series
SMM Basso, F Lumachi, R Behboo, G Favia
Endocrine Surgery Unit. Department of Surgical and Gastroenterological Sciences. University of Padova. Italy
475 Radiopharmaceutical and pharmaceuticals for the cure of prostate cancer
S Shukla, D Sc, R Cusumano, G Atzei, G Argirò, S Boemi, G Politano, P Iannantuono, C Cipriani, F Petrucci, A Alimonti, S Caroli, M Sinibaldi
1Department of Nuclear Medicine, Ospedale S. Eugenio, Roma, Roma Italy, 2Institute of Chromatography CNR Roma, Roma Italy, , 3Department of Urology, Aurelia Hospital, Roma Italy, , 4Laboratory of Applied Toxicology, Rma Italy
476 Influence of various administration routes on the antitumor activity of a somatostatin analog, TT-232
M Tejeda, D Gaál, G Kéri
1National Institute of Oncology, Budapest, Hungary, 2Institute of Biochemistry, Semmelweis Uni.Med.Sch, Budapest, Hungary
477 *Novel Drug Resistance-associated Protein and new plant derived modulators for overcoming drug resistance in human tumor cells
C Ramachandran, SJ Melnick, T Rabi, E Escalon
Research Institute, Miami Children's Hospital, Miami, FL 33155
478 Germline mutation screening of DNA repair genes MLH3 and MBD4 in typical and incomplete HNPCC families
Q Wang, G Montmain, C Lasset, V Bonadona, F Desseigne, JC Saurin, A Puisieux
1Centre Leon Berard, Lyon, France, 2Hopital Edouard Herriot, Lyon, France
479 Microphysiological testing for chemosensitivity of tumor cells with multiparametric microsensor-chips
AM Otto, M Brischwein, H Grothe, EM Motrescu, B Wolf
Technical University of Munich, Munich, Germany
480 EWS-FLI1 targeted vectorized antisense oligonucleotides inhibit a model of Ewing sarcoma in mice
A Maksimenko, G Lambert, JR Bertrand, E Fattal, F Subra, H Pinto-Alphandary, C Malvy, C Auclair, P Couvreur
1Laboratoire de physico-chimie, pharmacotechnie et biopharmacie, Faculté de Pharmacie, Chatenay Malabry, 2Laboratoire de physico-chimie et pharmacologie des macromolécules biologiques, Institut G. Roussy, Villejuif, France, 3Bioalliance Pharma SA, Boulevard du Général Martial Valin, 75015
481 Effects of serine protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF) on the blood-brain barrier (BBB) functions of cultured cerebral microvascular endothelial cells (CMEC)
P Megyeri, MD Deli, H Takahata, M Niwa, KM Pabst, MJ Pabst, CS Ábrahám
1Department of Pediatrics and Infectious Diseases, Albert Szent-Györgyi School of Medicine, University of Szeged, Szeged, Hungary, 2Laboratory of Molecular Neurobiology, Institute of Biophysics, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary, 3Department of Pharmacology, Nagasaki University School of Medicine, Nagasaki, Japan, 4Dental Research Center and Department of Biochemistry, University of Tennessee, Memphis, TN USA
482 Docetaxel in the treatment of advanced breast cancer
E Salminen
Department of Radiotherapy and Oncology, Turku University, Turku, Finland
483 Serum her-2 ecd and it's evolving role in management of breast cancer patients
A Voss, R Neumann
Bayer Vital GmbH, Leverkusen, Germany
484 Primary gastric lymphoma: a retrospective study
A Zeidman, E Ramadan, Z Fradin, Z Dreznik, M Mittelman
Rabin Medical Center, Hasharon Hospital, Petah-Tikva, Israel
485 The combination of APO2L/TRAIL with protein synthesis inhibitors or tyrosine kinase inhibitors inhibits pancreatic cancer growth in vitro and in vivo
J Standop, F Nozawa, M Schneider, RE Brand, XZ Ding, A Ulrich, K Picha, TE Adrian, PM Pour
1UNMC Eppley Institute, Department of Gastroenterology, and, Omaha, NE, 2Creighton University, Omaha, NE, 3Immunex Corp, Seattle, WA
486 Effects of roscovitine on DNA synthesis in normal and neoplastic glial cells.
MF Vita, JS Yakisich, J Boethius, O Lindblom, L Wallstedt, I Vargas, A Sidacon, M Cruz
Karolinska Institute, Stockholm, Stockholm, Sweden
487 Glycoglycerolipid analogues active in cancer chemoprevention: the role of the ester function on the inhibition of Epstein-Barr virus early antigen activation
F Ronchetti, D Colombo, F Compostella, A Scala, H Tokuda, H Nishino
1Department of Chemistry and Medical Biochemistry, University of Milan, Milan, Kyoto 602-0841, 2Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-0841, 3Department of Biochemistry, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan.
488 Regulation of proliferation/apoptosis equilibrium by map kinases in normal, hyperplastic and carcinomatous human prostate
M Royuela, MI Arenas, M Ricote, J Alfaro, MVT Lobo, R Vera, B Fraile, R Paniagua
University of Alcala, Alcala de Henares, Madrid Spain